Older people with diabetes are at greater risk of heart failure and strokes. SGLT2 inhibitors, which include the daily ...

CardioOncology, shows that administration of the SGLT2 inhibitor empagliflozin to pigs receiving anthracyclines preserves ...

Empagliflozin users had 741 events compared to 712 in the DPP4i group, corresponding to a non-significant HR of 1.04. For DR progression, empagliflozin users experienced fewer events (158) than ...

In keeping with current guidelines, either empagliflozin or dapagliflozin can be used for preventing AKI and CKD in patients with type 2 diabetes. Empagliflozin and dapagliflozin are equally effective ...

SGLT-2 inhibitors canagliflozin, empagliflozin, and dapagliflozin showed overall comparable effectiveness on cardiovascular outcomes in T2D.

Eli Lilly and Boehringer Ingelheim's blockbuster diabetes drug Jardiance (empagliflozin) has been granted approval by the US Food and Drug Administration (FDA) for a wider range of heart failure ...

First-line empagliflozin, taken once daily for 3 months, leads to a significant reduction in weight, body mass index (BMI), and waist circumference in patients with prediabetes and diabetes.

A team of scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC), working in collaboration with international partners, has designed a strategy for preventing the cardiotoxic ...

" Empagliflozin significantly reduced CI-AKI incidence in PCI patients by enhancing renal function markers, including eGFR ...

A team of scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC), working in collaboration with ...

Compared with people who had type 2 diabetes treated with empagliflozin (Jardiance), peers on canagliflozin (Invokana; HR 0.98, 95% CI 0.91-1.05) or dapagliflozin (Farxiga; HR 0.95, 95% CI 0.89-1. ...

In keeping with current guidelines, either empagliflozin or dapagliflozin can be used for preventing AKI and CKD in patients with type 2 diabetes. Empagliflozin and dapagliflozin are equally ...